PARSIPPANY, N.J., Oct. 1, 2018 /PRNewswire/ -- IBSA Pharma Inc., the U.S. pharmaceutical subsidiary of IBSA Group, the largest privately owned pharmaceutical company in Switzerland, will attend its first scientific meeting in the United States this week. IBSA Pharma Inc. will display at booth 403 at the Thyroid Expo during the 88th Annual Meeting of the American Thyroid Association. The annual meeting will be at the Marriott Marquis in Washington, D.C., from Oct. 3-7.
"As IBSA expands its presence into the U.S., we look forward to sharing our leadership in the treatment of thyroid disease," said Aldo Donati, CEO of IBSA Pharma. "By becoming the sole distributor and promoter of the Tirosint franchise, it will enable us to maximize its commercial value, and will provide us with the opportunity to introduce additional IBSA products in the future."
IBSA Pharma Inc. is planning to directly promote Tirosint® (levothyroxine sodium) capsules and aims to significantly increase the commercial and clinical support for the product by launching its own detailing sales force, which will roll out in the coming weeks. More information about Tirosint commercialization can be provided at the IBSA Pharma booth.
IBSA is a world leader in the treatment of thyroid disease, and is the developer, manufacturer and distributor of the first and only soft gelatin capsule formulation of levothyroxine.
IBSA Pharma Inc. is the U.S. pharmaceutical subsidiary of IBSA Group, a global pharmaceutical company based in Lugano, Switzerland. IBSA is present in nine major therapeutic areas worldwide, with a specific endocrinology focus in the United States. For more information please visit http://www.ibsagroup.com/ibsa-group/ibsa-usa.html
PM-00-18-0013
For Full Prescribing Information visit https://www.tirosint.com/wp-content/documents/Tirosint-PI.pdf.
SOURCE IBSA Pharma, Inc.
